Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Role Of Amphotericin B Upon Enhancement Of Protective Immunity Elicited By Oral Administration With Liposome-encapsulated-Japanese Encephalitis Virus Nonstructural Protein 1 (NS1) In Mice.

T. Lin, Chuan-Chang Chuang, Hui-Ling Hsu, Y. Liu, Wen-Po Lin, Chung-Chih Liang, Wen-Tssann Liu
Published 2010 · Biology, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Amphotericin B (AmB) is an antifungal antibiotic the activity of which has been associated with modulation of pro-inflammatory cytokines expression in cultured cells. Herein we reveal that co-administration with AmB enhances the immunogenicity of oral Lip-JENS1 vaccine which derived from liposomes functionalized with DSPC (distearoylphosphatidylcholine) and cholesterol (2:1, molar ratio)-bearing JE virus NS1 protein (600 microg ml(-1)). Oral single dose of Lip-JENS1 elicited a detectable serum NS1-specific IgG antibody response from a mouse model. Remarkably, the addition of AmB (125 microg per mouse), particularly, 2 h prior to, but not simultaneously with, the administration of Lip-JENS1 significantly enhanced the systemic antigen-specific antibody response, providing superior protection against lethal JEV challenges. Further, we observed AmB-induced the transcription of cytokine expression and translocation of transcriptional factor NF-kappaB from the cytoplasm to the nucleus for the murine macrophage J774A.1. Moreover, Peyer's-patch lymphocytes (PPL) from AmB-treated mice produced high levels of IL-1beta, IL-6 and TNF-alpha expression compared to the corresponding control of cells from non-treated mice. Taken together, the results suggest that AmB exerts a profound influence upon mucosal vaccination with Lip-JENS1, possibly playing an adjuvant-augmented role to "fine-tune" humoral as well as cellular immune response, thus conferring enhanced protective immunity for immunising individuals against JE infection.
This paper references
10.1086/315835
Amphotericin B induces expression of genes encoding chemokines and cell adhesion molecules in the human monocytic cell line THP-1.
P. Rogers (2000)
10.1016/S0065-3527(03)61010-9
Formalin-inactivated whole virus and recombinant subunit flavivirus vaccines.
K. Eckels (2003)
10.1016/0005-2736(91)90295-J
Small-volume extrusion apparatus for preparation of large, unilamellar vesicles.
R. Macdonald (1991)
10.1016/B978-0-323-35761-6.00033-X
Japanese encephalitis vaccines.
S. Halstead (2006)
10.1016/0165-2427(92)90075-2
The intestinal and serum humoral immune response of mice to orally administered antigens in liposomes: II. The response to liposome-entrapped bacterial proteins.
C. J. Clarke (1992)
10.1093/CLINIDS/14.SUPPLEMENT_1.S154
Current role of therapy with amphotericin B.
R. D. Meyer (1992)
10.1016/S0264-410X(03)00382-7
Comparison of protective efficacies of plasmid DNAs encoding Japanese encephalitis virus proteins that induce neutralizing antibody or cytotoxic T lymphocytes in mice.
E. Konishi (2003)
10.1016/S0167-7799(98)01220-7
Novel applications of liposomes.
D. Lasic (1998)
10.1016/S1368-7646(98)80034-4
Resistance to amphotericin B: emerging clinical and microbiological patterns.
T. Sterling (1998)
10.1086/423328
Proinflammatory cytokines and chemokines in humans with Japanese encephalitis.
P. M. Winter (2004)
10.1016/S0966-842X(03)00117-3
Antifungal agents: mechanisms of action.
F. Odds (2003)
Immunopotentiating effects of amphotericin B. I. Enhanced contact sensitivity in mice.
S. Shirley (1979)
Immunopotentiating effects of amphotericin B. II. Enhanced in vitro proliferative responses of murine lymphocytes.
S. Shirley (1979)
10.1016/S0264-410X(00)00037-2
New initiatives for the control of Japanese encephalitis by vaccination: minutes of a WHO/CVI meeting, Bangkok, Thailand, 13-15 October 1998.
T. Tsai (2000)
10.1128/AAC.49.4.1617-1621.2005
Secretion of Proinflammatory Cytokines and Chemokines during Amphotericin B Exposure Is Mediated by Coactivation of Toll-Like Receptors 1 and 2
R. Razonable (2005)
10.1016/0378-5173(92)90332-V
Effectiveness of liposomes as adjuvants of orally and nasally administered tetanus toxoid
H. O. Alpar (1992)
10.1016/J.VACCINE.2003.09.015
Construction of recombinant pseudorabies virus expressing NS1 protein of Japanese encephalitis (SA14-14-2) virus and its safety and immunogenicity.
Gaoyuan Xu (2004)
10.1016/S0168-3659(03)00093-2
Application of polyethyleneglycol (PEG)-modified liposomes for oral vaccine: effect of lipid dose on systemic and mucosal immunity.
Seiichiro Minato (2003)
Amphotericin B nephrotoxicity: the adverse consequences of altered membrane properties.
B. Sawaya (1995)
10.1093/CLINIDS/22.6.938
Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome).
R. Davidson (1996)
10.1006/VIRO.1996.0457
Generation and characterization of organ-tropism mutants of Japanese encephalitis virus in vivo and in vitro.
L. Chen (1996)
10.1128/JCM.42.11.5087-5093.2004
Development and Evaluation of an Enzyme-Linked Immunosorbent Assay for Quantifying Antibodies to Japanese Encephalitis Virus Nonstructural 1 Protein To Detect Subclinical Infections in Vaccinated Horses
E. Konishi (2004)
10.1016/0264-410X(96)82949-5
Influence of phospholipid composition on antibody responses to liposome encapsulated protein and peptide antigens.
N. Phillips (1996)
10.1128/AAC.37.10.2228
Augmentation of murine tumor necrosis factor production by amphotericin B in vitro and in vivo.
Y. Tokuda (1993)
10.1016/J.VACCINE.2006.04.066
Enhanced immune response by amphotericin B following NS1 protein prime-oral recombinant Salmonella vaccine boost vaccination protects mice from dengue virus challenge.
Wen-Tssann Liu (2006)
10.1016/S1286-4579(03)00047-9
Immune-mediated clearance of virus from the central nervous system.
G. K. Binder (2003)
10.1111/j.1348-0421.2006.tb03792.x
Analysis of Amphotericin B‐Induced Cell Signaling with Chemical Inhibitors of Signaling Molecules
K. Matsuo (2006)
10.1016/S0025-6196(12)60281-X
Antifungal agents used for deep-seated mycotic infections.
C. Terrell (1992)
10.1023/A:1020103109483
Antigen Delivery to Mucosa-Associated Lymphoid Tissues Using Liposomes as a Carrier
F. Zhou (2002)
10.1007/978-3-642-59403-8_6
Japanese encephalitis vaccines: current vaccines and future prospects.
T. Monath (2002)
10.1128/JVI.72.1.191-200.1998
DNA Immunization with Japanese Encephalitis Virus Nonstructural Protein NS1 Elicits Protective Immunity in Mice
Y. L. Lin (1998)
10.1146/ANNUREV.MI.44.100190.003245
Flavivirus genome organization, expression, and replication.
T. Chambers (1990)
10.1093/JAC/49.SUPPL_1.7
Amphotericin B: spectrum and resistance.
D. Ellis (2002)
10.1093/JAC/DKM255
Antifungal use in intensive care units.
E. Meyer (2007)
10.1093/JAC/42.4.469
Modulation of the pro- and anti-inflammatory cytokine balance by amphotericin B.
A. Vonk (1998)
10.1111/j.1439-0507.1995.tb00020.x
Infusion‐related toxicity of three different amphotericin B formulations and its relation to cytokine plasma levels
M. Arning (1995)
10.1128/IAI.61.1.23-31.1993
Association between virulence of Yersinia pestis and suppression of gamma interferon and tumor necrosis factor alpha.
R. Nakajima (1993)
10.1074/jbc.M306137200
The Antifungal Drug Amphotericin B Promotes Inflammatory Cytokine Release by a Toll-like Receptor- and CD14-dependent Mechanism*
K. Sau (2003)
10.1292/JVMS.59.1109
Application of liposomes for development of oral vaccines: study of in vitro stability of liposomes and antibody response to antigen associated with liposomes after oral immunization.
M. Han (1997)
10.1016/0168-3659(90)90133-E
Controlled vaccine release in the gut-associated lymphoid tissues. I. Orally administered biodegradable microspheres target the peyer's patches
J. Eldridge (1990)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar